# The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

> **NCT04542837** · PHASE2 · COMPLETED · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 55 (actual)

## Conditions studied

- HCC

## Interventions

- **BIOLOGICAL:** KN046
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT04542837
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-11
- **Primary completion:** 2022-02-23
- **Final completion:** 2024-03-15
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04542837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04542837, "The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04542837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*